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Capecitabine (Xeloda™, Hoffmann-La Roche, Basel, Switzer-
land) is an orally administered prodrug of 5-fluorouracil (5-FU)
that passes intact through the intestinal mucosa. It is activated
by a cascade of three enzymes to 5¢-deoxy-5-fluorocytidine
(5¢-DFCR), then to 5¢-deoxy-5-fluorouridine (5¢-DFUR), resulting
in an intratumoural release of 5-FU. This final, tumour-selective,
enzyme reaction is mediated by the tumour-associated angiogenic
factor, thymidine phosphorylase (TP). Capecitabine is cytotoxic
only after conversion to 5¢-DFUR and 5-FU. In human cancer
xenograft murine models, capecitabine was substantially more
active than 5-FU against colon CXF 280 and HCT 116, gastric
MKN 45 and GXF 97, breast MAXF 401 and MX-1, cervical
YUMOTO, HT-3 and SK-OV-3, ovarian NAKAJIMA, bladder
SCABER and hepatoma IH-3. This anti-tumour activity in mice
correlated with tumour 5-FU and blood 5¢-DFUR levels
(Investigational drug brochure: capecitabine 1997). The cytotoxi-
city of capecitabine correlated well with the activity ratio in
tumours of TP and dihydropyrimidine dehydrogenase, the
enzymes for the conversion of capecitabine to 5-FU and the catab-
olism of 5-FU respectively (Ishikawa et al, 1997). Furthermore, in
preclinical studies, paclitaxel and docetaxel were more active in
combination with capecitabine than with 5-FU or UFT. Recently, it
was demonstrated that thymidine phosphorylase is up-regulated in
murine model systems exposed to taxanes (Sawada et al, 1998).
In phase I studies of capecitabine as a single agent different
treatment schedules were investigated. Capecitabine was given
either continuously for 6 weeks or using an intermittent twice
daily schedule (Taguchi et al, 1996; Twelves et al, 1996; Budman
et al, 1998; Mackean et al, 1998). Each of those schedules were
active and common adverse events included diarrhoea, hand–foot
syndrome, nausea, vomiting, stomatitis and asthenia.
In a randomized phase II study of capecitabine in patients with
advanced colorectal cancer the following three treatment sched-
ules were evaluated: capecitabine 1331 mg m–2 day–1 continuously,
capecitabine 2510 mg m–2 day–1 for 14 days repeated every 21
days and capecitabine 1657 mg m–2 day–1 combined with leuco-
vorin 60 mg day–1 orally (p.o.) given intermittently (Findlay et al,
1997). Time to progression reported for these three administration
schedules was 17, 30 and 24 weeks respectively. Furthermore,
dose intensity appeared highest with the intermittent single-agent
schedule which was therefore selected for phase III evaluation.
Capecitabine was recently registered in the USA for treatment of
patients with breast cancer refractory to paclitaxel and anthra-
cyclines (Blum et al, 1999).
Docetaxel (Taxotere™, Rhône-Poulenc Rorer, Antony, France)
is an antimicrotubule agent that enhances polymerization of
tubulin into stable microtubules and inhibits microtubule depoly-
merization. This disrupts the equilibrium within the microtubule
system and ultimately leads to cell death (Guerrite-Voegelein et al,
1991; Ringel and Horwitz, 1991; Rowinsky and Donehower,
1991). In phase I studies of single-agent docetaxel the major dose-
limiting toxicity (DLT) was a short-lasting, dose-dependent,
schedule independent and non-cumulative neutropenia (Aapro et
al, 1992; Pazdur et al, 1992; Bisset et al, 1993; Burris et al, 1993;
Extra et al, 1993; Tomiak et al, 1993). Based on these phase I
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docetaxel was 100 mg m–2 given as a 1-h infusion every 3 weeks.
Phase II studies on docetaxel among others showed activity in
breast cancer (Ten Bokkel-Huinink et al, 1994; Chevallier et al,
1995), non-small-cell lung cancer (Cerny et al, 1994; Fossella et al,
1995; Miller et al, 1995), head and neck cancer (Catimel et al,
1994), gastric cancer (Sulkes et al, 1994), melanoma (Aamdal et al,
1994), soft tissue sarcoma (Van Hoesel et al, 1994) and pancreatic
cancer (De Forni et al, 1994). Again, the most important side-effect
was early but short-lasting neutropenia, that was complicated by
infection in 20% of the patients (Pronk et al, 1995). Alopecia was
common, but other toxicities were usually mild and included
nausea, vomiting, diarrhoea, mucositis, asthenia, infrequent hyper-
sensitivity reactions, skin reactions, nail changes, mild sensory
neuropathy and fluid retention. Corticosteroid premedication has
markedly reduced the incidence of hypersensitivity reactions
(Schrijvers et al, 1993) as well as the severity of fluid retention
(Piccart et al, 1997), and is now standard therapy.
In this phase I study the combination of capecitabine with
docetaxel was studied because given as single agents both drugs
are active in a variety of cancers and their toxicity profiles are only
partly overlapping. The aims of this study were: to determine the
maximum tolerated dose (MTD); to determine the safety profile of
the combination; to evaluate if there is any pharmacokinetic inter-
action between capecitabine and its metabolites and docetaxel; to
report any evidence of anti-tumour activity.
PATIENTS AND METHODS
Eligibility
Patients with histologically confirmed solid tumours for whom no
other therapy with greater potential benefit existed than the combi-
nation of capecitabine with docetaxel, were entered into this study.
The study was approved by the institutional ethics committee.
Eligibility criteria included: age 18 years and older; Karnofsky
performance status ³ 70; no more than two prior single-agent
chemotherapy regimens or one prior combination chemotherapy
regimen; no prior treatment with docetaxel and/or capecitabine;
normal bone marrow (haemoglobin > 9.0 g dl–1, granulocytes
> 1.5 ´ 109 l–1, platelet count > 100 ´ 109 l–), renal (serum creati-
nine < 1.5 ´ upper normal limit) and hepatic function (bilirubin
< 1.25 ´ upper normal limit, alkaline phosphatase < 2.5 ´ upper
normal limit, and transaminases < 1.5 ´ upper normal limit); uric
acid < 1.25 ´ upper normal limit, calcium < 2.88 mmol l–1, no
clinically significant cardiac disease or myocardial infarction
within the last 12 months; no radiation therapy within 4 weeks of
treatment start; no major surgery to the gastrointestinal tract, the
liver or kidney within 4 weeks of study entry which may impact on
the pharmacokinetics of capecitabine or docetaxel; no participa-
tion in any investigational drug study within 4 weeks preceding
treatment start; no history of peptic ulcer, ulcerative colitis, ulcera-
tive stomatitis and/or lack of physical integrity of the upper
intestinal tract. All patients provided written informed consent.
Pretreatment and follow-up studies
Before the start of treatment a medical history was taken and
physical examination, laboratory studies, electrocardiogram, chest 
X-ray and imaging studies, if appropriate, were performed.
Laboratory studies included a full blood count with differential
white count, sodium, potassium, creatinine, uric acid, serum
calcium, total protein, albumin, total bilirubin, ALAT, ASAT,
alkaline phosphatase and urinalysis.
History, physical examination and toxicity scoring according to
National Cancer Institute Common Toxicity Criteria (NCI-CTC)
(Brundage et al, 1993) were performed every 3 weeks and labora-
tory studies weekly. Formal tumour assessments were performed
after every 2 courses of chemotherapy according to standard
World Health Organization (WHO) response criteria (WHO
Handbook 1979).
Drug administration
Patients received treatment every 3 weeks. Docetaxel was admin-
istered on day 1 of each cycle as a 1-h intravenous (i.v.) infusion.
Capecitabine was to be administered orally within 30 min after the
end of a meal. The first cycle of capecitabine was given twice daily
starting on days 1–14. In the second cycle capecitabine was given
from day 3 to 14, the first 2 days of capecitabine being omitted to
allow pharmacokinetics samples to be taken. Subsequent cycles
combined capecitabine twice daily (b.i.d.) from day 1 to 14 with
docetaxel given on day 1. The prophylactic use of growth-factors
was not allowed.
Routine comedication
Oral dexamethasone (8 mg) or methylprednisolone (32 mg) was
given to all patients 12 and 3 h before docetaxel infusion, and then
12 and 24 h after the end of docetaxel infusion, followed by either
8 mg or 32 mg twice daily for an additional 3 days. No standard
i.v. anti-emetic prophylaxis was given.
Pharmacokinetic studies
For pharmacokinetic analyses, blood samples (5 ml) were
obtained from an indwelling i.v. canula in the contralateral arm,
and collected in haemogard vacutainer tubes (Becton Dickinson,
Meylan, France) containing EDTA as an anticoagulant. On days 1
and 14 blood was taken to measure levels of capecitabine and its
metabolites, and on days 1–3 and 22–24 to measure docetaxel
levels. Blood was collected on days 1–3 to explore any possible
interaction between the two drugs. Blood samples (5 ml) were
taken before the morning capecitabine dose and at 0.5, 1, 2, 3, 4, 5
and 7 h after drug administration; a final blood sample was taken
at 10 h after the morning capecitabine dose, but prior to the
evening drug administration. Blood samples (5 ml) for docetaxel
pharmacokinetics were taken before administration of docetaxel,
halfway through the infusion (0.5 h) and within 5 min of
completing the infusion (at 1 h). Additional samples were taken at
1.5, 2, 3, 5, 7, 10, 24, 30 and 48 h after the start of infusion. On day
14 blood was collected as described above, for the determination
of capecitabine pharmacokinetic parameters without potential
interference from docetaxel. On days 22–24 blood was collected
as described above, for the determination of docetaxel pharmaco-
kinetic parameters without potential interference from
capecitabine.
Concentrations of capecitabine and its metabolites 5¢-DFCR, 5¢-
DFUR, 5-FU and a-fluoro-b-alanine (FBAL) in plasma were
determined by liquid chromatography with mass-spectrometic
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1999).
Pharmacokinetics of capecitabine and its metabolites were esti-
mated by model-independent analysis using SAS Companion for
the Microsoft Environment version 6 (SAS Institute Inc., Cary,
NC, USA). The area under the plasma concentration–time curve
(AUC) was estimated by the trapezoidal rule using data until the
last measurable concentration, and was extrapolated to infinity
using the ratio of drug level at the last sampling point and the
apparent rate constant of the terminal phase. The terminal elimina-
tion half-life of the compounds was calculated using least-squares
linear regression of the final part of the plasma concentration–time
plot. Peak plasma concentrations (Cmax) and the time to reach the
peak concentration (tmax) were also determined graphically.
Plasma samples for docetaxel analysis were prepared by a single
solvent extraction and assayed by a validated reversed-phase high-
performance liquid chromatographic (HPLC) method with UV
detection as reported elsewhere (Loos et al, 1997). Docetaxel
concentration–time curves were analysed by determination of
slopes and intercepts of plotted curves with multi-exponential func-
tions. Initial parameter estimates were determined by the SIPHAR
version 4.0 program (Simed, Creteil, France) and improved using
an iterative numerical algorithm based on Powell’s method. Model
discrimination was assessed by a variety of considerations,
including visual inspection of the predicted curves, dispersion of
residuals, minimization of the sum of weighted squares residuals,
and the Akaike and Schwartz information criteria (Rowland and
Tozer, 1995). In all cases, concentration–time profiles were best
fitted to a bi-exponential model after zero-order input with
weighting according to l/Yobs. Final values of the iterated
parameters of the best fit equation were used to calculate kinetic
parameters using standard equations (Rowland and Tozer, 1995).
Statistical analysis
Kinetic parameters for capecitabine, its metabolites and docetaxel
are reported as arithmetic mean values ± standard deviation or as
median values (tmax only). Variability in parameters between the
various docetaxel dose levels was evaluated using the
Kruskal–Wallis statistic followed by a Dunn’s test. Interpatient
differences in pharmacokinetics were assessed from the coeffi-
cient of variation (CV), expressed as the ratio of the standard devi-
ation and the observed mean. To test parameter differences for
statistical significance among treatment courses, a two-tailed
paired Student’s t-test was performed. Probability values of less
than 0.05 were regarded as statistically significant. All statistical
calculations were performed using NCSS (version 5.X; Dr Jerry
Hintze, Kayesville, UT, USA) and STATGRAPHICS Plus (version
2; Manugistics Inc., Rockville, MA).
Doses
In this study dose escalation was performed in two phases, firstly
combining a fixed dose of capecitabine with increasing doses of
docetaxel. In the second phase the dose of capecitabine was
increased with a fixed dose of docetaxel demonstrated in the first
phase of escalation to be tolerable. The following dose levels of
capecitabine/docetaxel were explored: 825 mg m–2 b.i.d.–1 75 mg
m–2; 825 mg m–2 b.i.d 85 mg m–2; 825 mg m–2 b.i.d. 100 mg m–2;
1000 mg m–2 b.i.d. 100 mg m–2; 1000 mg m–2 b.i.d. 75 mg m–2;
1250 mg m–2 b.i.d. 75 mg m–2.
The docetaxel and capecitabine doses were escalated according
to a pre-established schedule. Dose escalation was continued until
DLTs were experienced in the first 2 cycles of treatment in two or
more of six patients, which was defined as the MTD. DLT was
defined as: (1) granulocytes < 0.5 ´ 109 l–1 for more than 7 days;
(2) grade 4 granulocytopenia with complications such as fever or
other non-haematological toxicities; (3) gastrointestinal toxicity
> grade 2; (4) skin toxicity (i.e. hand–foot syndrome) > grade 2.
RESULTS
A total of 33 patients entered this study. Patient characteristics are
given in Table 1. The most frequent tumour types were colorectal
cancer, adenocarcinoma of unknown primary (ACUP) and breast
cancer. All patients were evaluable for toxicity and tumour
response. Eight patients were not evaluable for pharmacokinetics;
in six patients blood was collected only on days 1–3, while in two
patients samples at essential time points were missing. The dose
levels studied, the number of patients at each dose level and the
number of evaluable courses at each dose level are given in Table
2.
A total of 123 courses were assessable for toxicity. No DLTs
were reported for the first 2 cycles at dose levels I and II.
Significant toxicities were observed in cycle 1 at dose levels III
and IV, consisting of febrile neutropenia. In one patient severe
anorexia was reported in cycle 1 at dose level IV, and another
patient showed in cycle 1 of dose level VI a reversible hepatotoxi-
city grade 3 consisting of an elevation of the serum bilirubin level.
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Table 1 Patient characteristics
Patients treated 33
Age
Median (range) 57 (33–74)
Karnofsky PS












Table 2 Patient accrual
Dose level Capecitabine Docetaxel No. patients No. cycles Range
(mg m–2 b.i.d.) (mg m–2)
I 825 75 4 14 1–6
II 825 85 6 32 3–6
III 825 100 6 16 1–6
IV 1000 100 5 14 1–6
V 1000 75 6 24 2–6
VI 1250 75 6 23 1–6
Total 33 123MTD was reached when the capecitabine dose was increased to
1000 mg m–2 b.i.d. (dose level IV). At this dose level all patients
showed grade 2–3 asthenia that was considered dose limiting. The
docetaxel dose was then reduced to 75 mg m–2, while the
capecitabine dose was escalated to full single-agent dose (dose
level VI). DLTs as defined in the protocol were not encountered.
No toxic deaths were reported.
Haematological toxicity
The relevant haematological toxicities are shown in Table 3.
Neutropenia grade 3 and 4, lasting < 7 days were observed at all
dose levels in 68% (range 31–88%) of all courses, but febrile
neutropenia requiring hospital admission was reported in only
three courses (2.4%). Anaemia grades 1 and 2 were common at all
dose levels and occurred in 89% of all courses; more severe
anaemia was not reported. Thrombocytopenia grade 4 requiring
platelet transfusion was only observed in 1 course.
Non-haematological toxicity
The most common non-haematological toxicities are shown in
Table 4. Nausea and vomiting were usually mild (grade 1 and 2)
and occurred in 33% and 11% of courses respectively. Grade 3
nausea was observed in three courses at dose levels II, III and VI,
while vomiting grade 3 was only reported in one course at dose
level VI. Mucositis grade 1–2 was documented in 42% of courses.
Severe mucositis was observed in two courses at dose levels II and
IV respectively. Diarrhoea grade 1–2 was reported in 33% of
courses and was severe in one course at dose level V. Asthenia (or
fatigue) was an important side-effect; grade 2–3 asthenia was
documented in 26% of courses. At dose level IV grade 2–3
asthenia was observed in all patients in 93% of courses, which was
considered dose-limiting. Alopecia was common at all dose levels.
Hand–foot syndrome was reported in 26.8% of courses which
required dose reduction in three patients and treatment delay in
two patients. Nail toxicity was observed in 24% of courses and
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Table 3 Haematological toxicitya
Dose level I II III IV V VI Total (%)
Capecitabine (mg m–2 b.i.d.) 825 825 825 1000 1000 1250
Docetaxel (mg m–2) 75 85 100 100 75 75
No. evaluable courses 14 32 16 14 24 23 123
Neutropenia G3 3 13 1 2 6 4 29 (24)
G4 6 15 4 9 7 13 54 (44)
Febrile neutropenia – 1 1 1 – – 3 (2.4)
Thrombopenia G1–2 – 4 – – – 1 5 (4)
G3–4 – 1 – – – – 1 (0.8)
Anaemia G1–2 13 28 11 13 23 22 110 (89)
aNo. of courses affected/total courses.
Table 4 Non-haematological toxicitya
Dose level I II III IV V VI Total (%)
Capecitabine (mg m–2 b.i.d.) 825 825 825 1000 1000 1250
Docetaxel (mg m–2) 75 85 100 100 75 75
No. evaluable courses 14 32 16 14 24 23 123
Nausea G 1–2 3 15 4 7 8 3 40 (33)
G 3–4 – 1 1 – – 1 3 (2.4)
Vomiting G 1–2 2 – 2 2 5 3 13 (11)
G 3–4 – – – – – 1 1 (0.8)
Diarrhoea G 1–2 8 9 4 4 13 3 41 (33)
G 3–4 – – – – 1 – 1 (0.8)
Mucositis G 1–2 6 11 8 8 13 5 51 (42)
G 3–4 – 1 – 1 – – 2 (1.6)
Asthenia G 1 5 11 4 – 3 7 30 (24)
G 2–3 2 4 1 13 6 6 32 (26)
Alopecia G 1–2 9 24 12 9 18 18 90 (73)
Hand–foot G 1–2 4 15 3 – 8 2 32 (26)
G 3–4 – 1 – – – – 1 (0.8)
Nail toxicityb 4 7 1 4 6 7 29 (24)
Neurotoxicity G 1–2 4 7 5 4 5 1 26 (21)
Oedema G 1–2 6 2 – – 1 1 10 (8)
Allergy – 3 3 1 1 1 9 (7)
aNo. of courses affected/total courses; bsee text.was complicated with paronychia in four patients. One patient
treated at dose level II developed septic paronychia that required
dose reduction. Docetaxel related toxicities like neuropathy,
oedema and allergy were mild and never a reason to stop therapy.
Tolerability of multiple cycles
Three patients at dose level II, one patient at dose level IV and one
patient at dose level V underwent dose reduction. The method of
dose reduction was not pre-established. In two of the three patients
at dose level II the dose of both drugs was reduced by 25%
because of hand–foot syndrome in cycle 3 in one patient and in
cycle 4 in the other patient. One patient at dose level II developed
thrombocytopenia grade 4 in cycle 4 that required a dose reduction
by 50% of only capecitabine, because it was assumed that
capecitabine rather than docetaxel contributed to the occurrence of
thrombo-cytopenia. The patient at dose level IV underwent a dose
reduction by 25% of both drugs in cycle 2 because of grade 2
nausea and anorexia. The patient at dose level V underwent a dose
reduction by 25% of both drugs because of hand–foot syndrome in
cycle 4. Treatment was delayed because of hand–foot syndrome in
two patients at dose level II after cycle 3 and 4 respectively. Both
hand–foot syndrome and nail toxicity were sometimes problematic
with prolonged treatment. However, no other cumulative toxicity
was observed. The dose intensity of this treatment schedule was
high at all dose levels (0.95–1), but lower at dose level IV (0.84).
Pharmacokinetics
In the pharmacokinetic calculations only patients with complete
AUC were taken into consideration. Capecitabine pharmaco-
kinetics were characterized by a rapid absorption after oral dosing,
with peak plasma levels occurring at approximately 1 h. In the
majority of patients the main circulating compounds were 5¢-
DFUR (the immediate precursor of 5-FU) and the 5-FU metabolite
FBAL. The pharmacokinetic characteristics of capecitabine and
the metabolities are listed in Table 5 as a function of the dose. In
general, the pharmacokinetics demonstrated high interpatient vari-
ability. Overall the kinetic data of capecitabine and the metabol-
ites in the presence of docetaxel indicate a very minor effect of
co-treatment with the taxane (Table 5). However, whereas
identical parameters were observed for capecitabine, 5¢-DFCR,
5¢-DFUR and FBAL between study courses, the systemic expo-
sure to 5-FU tended to decrease in the presence of docetaxel. This
effect was particularly striking at the 1250 mg m–2 b.i.d. dose
level, resulting in a 1.8- and 1.9-fold lower values for Cmax and
AUC (Table 5).
The plasma concentration-time profiles for docetaxel were
similar with and without capecitabine co-treatment. In both cases,
disposition phases of docetaxel exhibited a bi-exponential decay
and could be best fitted to a two-compartmental model. The mean
estimated pharmacokinetic parameters of docetaxel for both study
courses are summarized as a function of the treatment cohort in
Table 6.
Substantial interpatient kinetic variability was apparent with
values for the coefficient of variation up to 50%. There were no
significant differences in dose-normalized pharmacokinetic para-
meters between the docetaxel dose levels, as shown by the dose-
independent values for docetaxel plasma clearance. The mean
overall total body clearance of docetaxel across all dose levels
without capecitabine co-treatment was 25.4 ± 8.79 l h–1 m–2
(mean ± standard deviation). Docetaxel pharmacokinetics were
not significantly altered by co-treatment with capecitabin
(P < 0.05 for all kinetic parameters using two-tailed Student’s
t-test), indicating no mutual kinetic interaction between these two
drugs (Table 6).
Responses
Two complete responses were documented in a patient with ACUP
(total disappearance of previously found metastatic sites: lymph-
nodes, adrenal glands and soft tissue) and in another patient with
gastric cancer (metastatic sites: lymph nodes and pancreatic
region). Time to progression was 8 months in both patients. Partial
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Table 5 Summary of paired capecitabine and metabolities pharmacokinetics in the presence or absence of docetaxela
Capecitabine (mg m–2 b.i.d.) 825 825 1000 1000 1250 1250
Docetaxel (mg m–2) 75,100 – 75,100 – 75 –
Capecitabine
t1/2 (h) 0.59 ± 0.31 0.55 ± 0.31 0.69 ± 0.29 0.70 ± 0.32 0.58 ± 0.28 0.66 ± 0.38
AUC (mg h ml–1) 5.19 ± 3.01 3.82 ± 1.31 5.58 ± 2.96 5.66 ± 2.38 7.01 ± 4.21 6.39 ± 0.83
5¢-DFCR
t1/2 (h) 0.82 ± 0.24 0.86 ± 0.38 0.80 ± 0.13 0.87 ± 0.20 0.87 ± 0.24 0.76 ± 0.09
AUC (mg h ml–1) 3.56 ± 2.35 4.35 ± 2.65 7.61 ± 3.35 8.23 ± 3.95 11.9 ± 5.24 9.78 ± 1.08
5¢-DFUR
t1/2 (h) 0.65 ± 0.12 0.70 ± 0.23 0.79 ± 0.32 0.71 ± 0.18 0.81 ± 0.27 0.63 ± 0.12
AUC (mg h ml–1) 12.3 ± 3.20 10.8 ± 3.24 12.6 ± 2.27 11.8 ± 3.78 16.1 ± 3.70 16.9 ± 2.37
5-FU
t1/2 (h) 0.71 ± 0.16 0.70 ± 0.17 0.87 ± 0.47 0.72 ± 0.18 0.92 ± 0.50 0.68 ± 0.09
AUC (mg h ml–1) 0.36 ± 0.19 0.41 ± 0.15 0.48 ± 0.15 0.61 ± 0.31 0.42 ± 0.13 0.80 ± 0.28
FBAL
t1/2 (h) 2.43 ± 0.36 2.83 ± 0.45 2.76 ± 0.61 2.96 ± 0.50 2.11 ± 0.36 2.24 ± 0.11
AUC (mg h ml–1) 16.8 ± 5.38 21.1 ± 4.85 23.3 ± 9.55 25.4 ± 9.65 20.8 ± 2.29 20.4 ± 0.61
aData were obtained from 16, ten and four patients treated at capecitabine dose levels of 825, 1000 and 1250 mg m–2 b.i.d. respectively.
Kinetic terms are arithmetic mean values ± standard deviation (t1/2, and AUC). Abbreviations: t1/2, terminal elimination half-life; AUC, area
under the plasma concentration–time curve; 5¢-DFCR, 5¢-deoxy-5-fluorocytidine; 5¢-DFUR, 5¢-deoxy-5-fluorouridine; 5-FU, 5-fluorouracil;
(FUH2), dihydro-5-fluorouracil; FBAL, a-fluoro-b-alanineresponses were reported in two patients with breast cancer
(metastatic sites: liver in 1 patient and skin and lymphnodes in the
other patient) and in one patient with colon cancer (metastatic
sites: liver and peritoneal). Time to progression in these patients
was 6 months for the patients with breast cancer and 9.5 months
for the patient with colon cancer.
DISCUSSION
Capecitabine is a new orally available tumour-selective fluoro-
pyrimidine carbamate, that is bioactivated by a three-enzyme
process to provide prolonged high levels of the active moiety,
5-FU, in tumour cells (Investigational drug brochure: capecitabine
1997). Capecitabine is active against advanced breast cancer that
is resistant to anthracyclines and taxanes (Blum et al, 1999). In
most cases, however, combination therapy is prefered to single-
agent treatment. Docetaxel was selected for the combination with
capecitabine, since it is probably the most active single agent in the
treatment of breast cancer (Ten Bokkel Huinink et al, 1994;
Chevallier et al, 1995). In addition, docetaxel and capecitabine
have toxicity profiles that only partially overlap. In this phase I
study we have shown that capecitabine and docetaxel can be
combined safely and effectively, giving both agents at doses where
they possess single-agent activity.
Dose escalation was performed in 2 phases, firstly combining a
fixed dose of capecitabine with increasing doses of docetaxel. In
the second phase the dose of capecitabine was increased with a
fixed dose of docetaxel demonstrated to be tolerable in the first
phase of dose escalation. A starting dose of 75 mg m–2 of docetaxel
was chosen as phase I studies showed this dose to be active with
a favourable toxicity profile (Pronk et al, 1995). A dose of
825 mg m–2 bid of capecitabine when given as an intermittent
schedule was well tolerated and active in phase I studies (Budman
et al, 1998; Mackean et al, 1998). These starting doses were
combined as it was anticipated that this combination would be
active and tolerable.
The most important non-haematological toxicity was asthenia
which was considered dose-limiting when 1000 mg m–2 b.i.d. of
capecitabine was combined with 100 mg m–2 of docetaxel (dose
level IV). Other DLTs as foreseen in the protocol were not encoun-
tered. The major haematological toxicity of the combination was
neutropenia grade 3 and 4, lasting < 7 days, which occurred in
68% of all courses. However, in only three courses was
neutropenia complicated with fever requiring hospital admission.
Gastrointestinal toxicity was frequent but again usually mild.
Hand–foot syndrome, which is characteristic of capecitabine, was
reported in 26.8% of courses; in most cases this was not severe and
only required dose reduction in three patients and treatment delay
in two patients. The incidence of docetaxel-specific toxicities like
fluid retention and allergy was low and did not constitute a major
clinical problem, probably because all patients received corticos-
teroid comedication. Neurotoxicity was also mild and only
occurred in 21% of courses, which is less than reported in patients
treated with docetaxel as a single agent (Hilkens et al, 1996).
However, nail toxicity was sometimes problematic in patients with
prolonged treatment.
The evaluation of pharmacokinetic interaction when combining
novel, active chemotherapy agents is extremely relevant. In this
study the possible up-regulation of TP by taxanes raised the possi-
bility that exposure to 5-FU may be increased by co-administration
of docetaxel. Pharmacokinetic studies were performed for
capecitabine as a single agent and in the presence of docetaxel.
Plasma peak concentrations for the drug were reached shortly after
oral dosing. As predicted by earlier investigations, capecitabine
was extensively metabolized by hepatic carboxylesterases into 5¢-
DFCR with subsequent cytidine deamination to form the 5-FU
precursor 5¢-DFUR (Budman et al, 1998; Mackean et al, 1998).
The latter compound was, together with the 5-FU metabolite
FBAL, the main circulating compound in the majority of patients.
The pharmacokinetics of capecitabine showed high interpatient
variability and were highly consistent with recently published
values obtained in patients treated at a single-agent dose of
1657 mg m–2 day–1 (Budman et al, 1998). Overall, the kinetic data
of capecitabine and its metabolites were similar for capecitabine as
a single agent and in the presence of docetaxel. However, the
systemic exposure to 5-FU tended to decrease in the presence of
docetaxel. This effect was particularly striking at the 1250 mg m–2
b.i.d. dose level. More pharmacokinetic studies will be needed to
explain the significance of this observation.
The plasma concentration-time profiles for docetaxel given as a
single agent and with capecitabine were similar. The interpatient
kinetic variability, particularly at the 75 mg m–2 dose level, was
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Table 6 Summary of paired docetaxel pharmacokinetics in the presence or absence of capecitabinea
Docetaxel Capecitabine nC max t1/2 AUC CL Vss
(mg m–2) (mg m–2 b.i.d.) (mg ml–1) (h) (mg h ml–1) (l h–1 m–2) (l m–2) (h)
75 825 3 2.25 ± 0.23 2.83 ± 1.19 2.47 ± 0.35 30.9 ± 4.53 41.3 ± 12.9
75 – 3 2.10 ± 1.04 1.81 ± 0.96 2.32 ± 1.16 32.8 ± 15.6 33.3 ± 15.9
85 825 4 2.57 ± 0.53 7.52 ± 5.42 3.74 ± 1.09 25.0 ± 7.92 63.1 ± 24.4
85 – 4 2.64 ± 0.47 5.88 ± 2.87 3.37 ± 0.97 27.7 ± 8.86 68.5 ± 24.8
100 825 4 3.28 ± 0.78 12.2 ± 9.24 4.45 ± 1.26 24.5 ± 7.00 123 ± 89.9
100 – 4 3.96 ± 1.76 9.81 ± 4.62 6.07 ± 2.48 18.7 ± 5.44 75.9 ± 44.3
100 1000 3 3.78 ± 0.56 12.4 ± 9.24 5.09 ± 0.97 20.4 ± 3.86 86.7 ± 1.75
100 – 3 3.73 ± 0.06 9.39 ± 2.88 5.13 ± 0.51 19.7 ± 2.01 72.0 ± 28.5
75 1000 6 2.29 ± 0.11 6.90 ± 3.71 3.05 ± 0.56 25.4 ± 4.44 82.0 ± 42.8
75 – 6 2.54 ± 0.70 5.40 ± 2.41 3.45 ± 1.29 24.3 ± 7.11 57.4 ± 14.2
75 1250 5 2.34 ± 0.67 8.15 ± 9.05 3.25 ± 1.08 26.1 ± 9.45 95.9 ± 100
75 – 5 2.78 ± 0.55 8.46 ± 9.36 3.16 ± 0.70 25.1 ± 6.23 115 ± 134
aKinetic terms are mean values ± standard deviation. Abbreviations: n, number of patients with complete paired kinetic data; Cmax, peak plasma level; t1/2,
terminal elimination half-life; AUC, area under the plasma concentration-time curve; CL, total body clearance; Vss, volume of distribution at steady state.substantial which could in part be accounted for by missing
samples at essential time points in some patients. (There was no
systemic reason for the missing data.) The mean overall total body
clearance of docetaxel as a single agent across all dose levels was
25.4 ± 8.79 l h–1 m–2 (mean ± standard deviation). This is consis-
tent with previously published values obtained in phase 1 clinical
trials on docetaxel as a single agent (Bruno and Sanderink 1993).
These data indicate that capecitabine has no significant effect on
docetaxel pharmacokinetics.
The combination of capecitabine and docetaxel is clearly active
with two complete responses (one patient with ACUP, one with
gastric cancer) and three partial responses (two with breast cancer,
one with colon cancer). The antitumour activity of capecitabine as
a single agent in patients with advanced breast cancer has been
demonstrated in series of phase II trials. A randomized phase II
study in women aged 55 years or older compared capecitabine
with CMF as first-line treatment (O’Shaugnessy et al, 1998);
preliminary results showed that capecitabine monotherapy is at
least comparable with CMF combination chemotherapy. However,
severe hand–foot syndrome and diarrhoea were more frequent in
the capecitabine treatment arm. In a multicenter phase II trial in
patients with paclitaxel-refractory metastatic breast cancer, who
were all also pretreated with anthracyclines, patients received a
dose of 2510 mg m–2 day–1 given for 2 weeks followed by a 1-
week rest period, repeated every 3 weeks (Blum et al, 1998). The
toxicity profile was acceptable and the response rate was 20%,
with a median response duration of 8.1 months and a median
survival of 12.8 months. The median time to disease progression
was 93 days. This study shows that capecitabine is active in pacli-
taxel/anthracycline resistant breast cancer, and suggests that there
is no cross-resistance between capecitabine and taxanes, a further
justification for the use of capecitabine and docetaxel in combina-
tion. The combination of capecitabine with paclitaxel is also under
investigation in a phase I study in patients with previously treated
metastatic breast cancer (Khoury et al, 1998). The combination
appears to be active, even in patients who had prior bone marrow
transplantation.
Based on the experience obtained in this phase I study, repeated
cycles of capecitabine 825 mg m–2 bid combined with docetaxel
100 mg m–2 or capecitabine 1250 mg m–2 b.i.d. with docetaxel
75 mg m–2 are both feasible. A randomized phase III study
comparing the combination of capecitabine 1250 mg m–2 and
docetaxel 75 mg m–2 with docetaxel 100 mg m–2 as a single agent
is ongoing in patients with metastatic breast cancer as first-line
treatment.
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